Albany Molecular Research Inc (AMRI) financial statements (2020 and earlier)

Company profile

Business Address 21 CORPORATE CIRCLE
ALBANY, NY 12203-5154
State of Incorp. DE
Fiscal Year End December 31
SIC 8731 - Commercial Physical and Biological Research (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments42355245314449
Cash and cash equivalents42355245314449
Restricted cash and investments0000133
Receivables145143147129102104116
Inventory, net of allowances, customer advances and progress billings186174167202939489
Inventory186174167202939489
Other undisclosed current assets30332729302923
Total current assets:404385393404257274280
Noncurrent Assets
Property, plant and equipment362360365376222217210
Long-term investments and receivables   1 11
Long-term investments   1 11
Intangible assets, net (including goodwill)407395396421288294290
Goodwill239231231241171173169
Intangible assets, net (excluding goodwill)168164165180117121120
Derivative instruments and hedges65195147374276
Other noncurrent assets4445333
Other undisclosed noncurrent assets1113 35
Total noncurrent assets:838778817854550560585
TOTAL ASSETS:1,2421,1641,2101,258807834866
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:117109111127727461
Employee-related liabilities11120018
Taxes payable2434   
Other undisclosed accounts payable and accrued liabilities11410497123727353
Debt452343636131416
Derivative instruments and hedges, liabilities    6  
Deferred revenue and credits20201315101415
Other undisclosed current liabilities34155018
Total current liabilities:59316717618310310299
Noncurrent Liabilities
Long-term debt and lease obligation196607604606371374374
Long-term debt, excluding current maturities196607604606371374374
Liabilities, other than long-term debt13792131131705589
Accounts payable and accrued liabilities3442233
Deferred tax liabilities, net3537404520  
Liability, pension and other postretirement and postemployment benefits18181920777
Other liabilities16161717433
Derivative instruments and hedges, liabilities65195147374276
Other undisclosed noncurrent liabilities     1716
Total noncurrent liabilities:333700735738441446479
Total liabilities:925867911920544547578
Stockholders' equity
Stockholders' equity attributable to parent317297299338263287287
Common stock0000000
Treasury stock, value(71)(71)(69)(69)(69)(69)(68)
Additional paid in capital408403400398304301296
Accumulated other comprehensive loss(6)(32)(40)(14)(18)(12)(18)
Retained earnings (accumulated deficit)(14)(4)723466777
Total stockholders' equity:317297299338263287287
TOTAL LIABILITIES AND EQUITY:1,2421,1641,2101,258807834866

Income statement (P&L) ($ in millions)

6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
Revenues
(Revenue, Net)
173164191153121106126
Cost of revenue(132)(125)(157)(126)(83)(82)(93)
Cost of goods and services sold(132)(123)(153)(123)(82)(79)(93)
Gross profit:41393526382434
Operating expenses(43)(37)(40)(42)(32)(28)(8)
Other undisclosed operating loss      (19)
Operating income (loss):(2)2(5)(16)6(4)6
Nonoperating income (expense)(1)(1)6(1)(6)(1)0
Other nonoperating income (expense)(1)(1)6(1)(6)(1) 
Interest and debt expense(13)(13)(13)(13)(7)(7)(7)
Loss from continuing operations before income taxes:(15)(12)(12)(29)(6)(12)(0)
Income tax expense (benefit)51(3)5(15)22
Net income (loss) available to common stockholders, diluted:(10)(11)(15)(23)(21)(10)2

Comprehensive Income ($ in millions)

6/30/2017
Q2
3/31/2017
Q1
12/31/2016
Q4
9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
Net income (loss):(10)(11)(15)(23)(21)(10)2
Other comprehensive income (loss)(0)7(26)(0)(0)6(4)
Comprehensive loss:(10)(3)(41)(24)(21)(4)(3)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent26  4(5)  
Comprehensive income (loss), net of tax, attributable to parent:16(3)(41)(19)(27)(4)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: